Risk of incident chronic kidney disease in metabolically healthy obesity and metabolically unhealthy normal weight: A systematic review and meta-analysis.
chronic kidney disease
eGFR
metabolic health
metabolic syndrome
obesity
Journal
Obesity reviews : an official journal of the International Association for the Study of Obesity
ISSN: 1467-789X
Titre abrégé: Obes Rev
Pays: England
ID NLM: 100897395
Informations de publication
Date de publication:
30 Oct 2023
30 Oct 2023
Historique:
revised:
27
09
2023
received:
04
02
2023
accepted:
03
10
2023
medline:
31
10
2023
pubmed:
31
10
2023
entrez:
31
10
2023
Statut:
aheadofprint
Résumé
Studies have reported inconsistent results about the risk of incident chronic kidney disease (CKD) in people with metabolically healthy obesity (MHO). We designed this systematic review and meta-analysis to evaluate the risk of developing CKD in people with MHO and metabolically unhealthy normal weight (MUNW). We used a predefined search strategy to retrieve eligible studies from multiple databases up to June 20, 2022. Random-effects model meta-analyses were implied to estimate the overall hazard ratio (HR) of incident CKD in obesity phenotypes. Eight prospective cohort studies, including approximately 5 million participants with a median follow-up ranging between 3 and 14 years, were included in this meta-analysis. Compared to the metabolically healthy normal weight (MHNW), the mean differences in cardiometabolic and renal risk factors in MHO, MUNW, and metabolically unhealthy obesity (MUO) were evaluated with overall HR of 1.42, 1.49, and 1.84, respectively. Compared to MHNW, the mean estimated glomerular filtration rate (eGFR) and high-density lipoprotein (HDL) were significantly lower, and low-density lipoprotein (LDL), blood pressure, blood glucose, and triglycerides were higher in MHO and MUNW. In conclusion, MHO and MUNW are not benign conditions and pose a higher risk for incident CKD. Obesity, whether in the presence or absence of metabolic health, is a risk factor for CKD.
Types de publication
Journal Article
Review
Langues
eng
Sous-ensembles de citation
IM
Subventions
Organisme : National Natural Science Foundation of China
ID : 81770880
Organisme : National Natural Science Foundation of China
ID : 81800788
Organisme : National Natural Science Foundation of China
ID : 81970762
Organisme : National Natural Science Foundation of China
ID : 8217033609
Organisme : National Natural Science Foundation of China
ID : 82170900
Organisme : Science and Technology Department of Hunan Province
ID : 2015JC3012
Organisme : Science and Technology Department of Hunan Province
ID : 2020SK2080
Organisme : Changsha City
ID : k1906019
Organisme : Changsha City
ID : kq1901118
Informations de copyright
© 2023 World Obesity Federation.
Références
Coresh J, Selvin E, Stevens LA, et al. Prevalence of chronic kidney disease in the United States. Jama. 2007;298(17):2038-2047. doi:10.1001/jama.298.17.2038
Global, regional, and national burden of chronic kidney disease, 1990-2017: a systematic analysis for the Global Burden of Disease Study 2017. Lancet. 2020;395(10225):709-733.
Eckardt KU, Coresh J, Devuyst O, et al. Evolving importance of kidney disease: from subspecialty to global health burden. Lancet. 2013;382(9887):158-169. doi:10.1016/S0140-6736(13)60439-0
Go AS, Chertow GM, Fan D, McCulloch CE, Hsu CY. Chronic kidney disease and the risks of death, cardiovascular events, and hospitalization. N Engl J Med. 2004;351(13):1296-1305. doi:10.1056/NEJMoa041031
Foster MC, Hwang SJ, Larson MG, et al. Overweight, obesity, and the development of Stage 3 CKD: the Framingham heart study. Am J Kidney Dis. 2008;52(1):39-48. doi:10.1053/j.ajkd.2008.03.003
Guh DP, Zhang W, Bansback N, Amarsi Z, Birmingham CL, Anis AH. The incidence of co-morbidities related to obesity and overweight: a systematic review and meta-analysis. BMC Public Health. 2009;9(1):88. doi:10.1186/1471-2458-9-88
Ting SM, Nair H, Ching I, Taheri S, Dasgupta I. Overweight, obesity and chronic kidney disease. Nephron Clin Pract. 2009;112(3):c121-c127.
Chang AR, Grams ME, Ballew SH, et al. Adiposity and risk of decline in glomerular filtration rate: meta-analysis of individual participant data in a global consortium. BMJ. 2019;364:k5301. doi:10.1136/bmj.k5301
Lu Y, Hajifathalian K, Ezzati M, et al. Metabolic mediators of the effects of body-mass index, overweight, and obesity on coronary heart disease and stroke: a pooled analysis of 97 prospective cohorts with 1.8 million participants. Lancet. 2014;383(9921):970-983. doi:10.1016/S0140-6736(13)61836-X
Rey-López JP, de Rezende LF, Pastor-Valero M, Tess BH. The prevalence of metabolically healthy obesity: a systematic review and critical evaluation of the definitions used. Obes Rev. 2014;15(10):781-790. doi:10.1111/obr.12198
Primeau V, Coderre L, Karelis AD, et al. Characterizing the profile of obese patients who are metabolically healthy. Int J Obes (Lond). 2011;35(7):971-981. doi:10.1038/ijo.2010.216
Stefan N, Kantartzis K, Machann J, et al. Identification and characterization of metabolically benign obesity in humans. Arch Intern Med. 2008;168(15):1609-1616. doi:10.1001/archinte.168.15.1609
Opio J, Croker E, Odongo GS, Attia J, Wynne K, McEvoy M. Metabolically healthy overweight/obesity are associated with increased risk of cardiovascular disease in adults, even in the absence of metabolic risk factors: a systematic review and meta-analysis of prospective cohort studies. Obes Rev. 2020;21(12):e13127. doi:10.1111/obr.13127
Zheng R, Zhou D, Zhu Y. The long-term prognosis of cardiovascular disease and all-cause mortality for metabolically healthy obesity: a systematic review and meta-analysis. J Epidemiol Community Health. 2016;70(10):1024-1031. doi:10.1136/jech-2015-206948
Lin CJ, Chang YC, Cheng TY, Lo K, Liu SJ, Yeh TL. The association between metabolically healthy obesity and risk of cancer: a systematic review and meta-analysis of prospective cohort studies. Obes Rev. 2020;21(10):e13049. doi:10.1111/obr.13049
Bell JA, Kivimaki M, Hamer M. Metabolically healthy obesity and risk of incident type 2 diabetes: a meta-analysis of prospective cohort studies. Obes Rev. 2014;15(6):504-515. doi:10.1111/obr.12157
Yang Y. Metabolically healthy obesity and risk of incident chronic kidney disease in a Korean cohort study. Iran J Public Health. 2019;48(11):2007-2015.
Hashimoto Y, Tanaka M, Okada H, et al. Metabolically healthy obesity and risk of incident CKD. Clin J Am Soc Nephrol. 2015;10(4):578-583. doi:10.2215/CJN.08980914
Jung CH, Lee MJ, Kang YM, et al. The risk of chronic kidney disease in a metabolically healthy obese population. Kidney Int. 2015;88(4):843-850. doi:10.1038/ki.2015.183
Chang Y, Ryu S, Choi Y, et al. Metabolically healthy obesity and development of chronic kidney disease: a cohort study. Ann Intern Med. 2016;164(5):305-312. doi:10.7326/M15-1323
Worldwide trends in body-mass index, underweight, overweight, and obesity from 1975 to 2016: a pooled analysis of 2416 population-based measurement studies in 128·9 million children, adolescents, and adults. Lancet. 2017;390(10113):2627-2642.
Chang AR, Surapaneni A, Kirchner HL, et al. Metabolically healthy obesity and risk of kidney function decline. Obesity (Silver Spring). 2018;26(4):762-768. doi:10.1002/oby.22134
Stefan N, Schulze MB. Metabolic health and cardiometabolic risk clusters: implications for prediction, prevention, and treatment. Lancet Diabetes Endocrinol. 2023;11(6):426-440. doi:10.1016/S2213-8587(23)00086-4
Eckel N, Meidtner K, Kalle-Uhlmann T, Stefan N, Schulze MB. Metabolically healthy obesity and cardiovascular events: a systematic review and meta-analysis. Eur J Prev Cardiol. 2016;23(9):956-966. doi:10.1177/2047487315623884
Cameron AJ, Shaw JE, Zimmet PZ. The metabolic syndrome: prevalence in worldwide populations. Endocrinol Metab Clin North Am. 2004;33(2):351-375. table of contents
Eckel RH, Grundy SM, Zimmet PZ. The metabolic syndrome. Lancet. 2005;365(9468):1415-1428. doi:10.1016/S0140-6736(05)66378-7
Grams ME, Sang Y, Ballew SH, et al. Evaluating glomerular filtration rate slope as a surrogate end point for ESKD in clinical trials: an individual participant meta-analysis of observational data. J Am Soc Nephrol. 2019;30(9):1746-1755. doi:10.1681/ASN.2019010008
Fox CS, Larson MG, Leip EP, Culleton B, Wilson PW, Levy D. Predictors of new-onset kidney disease in a community-based population. Jama. 2004;291(7):844-850. doi:10.1001/jama.291.7.844
Muntner P, Coresh J, Smith JC, Eckfeldt J, Klag MJ. Plasma lipids and risk of developing renal dysfunction: the atherosclerosis risk in communities study. Kidney Int. 2000;58(1):293-301. doi:10.1046/j.1523-1755.2000.00165.x
Hunsicker LG, Adler S, Caggiula A, et al. Predictors of the progression of renal disease in the modification of diet in renal disease study. Kidney Int. 1997;51(6):1908-1919. doi:10.1038/ki.1997.260
Nashar K, Egan BM. Relationship between chronic kidney disease and metabolic syndrome: current perspectives. Diabetes Metab Syndr Obes. 2014;7:421-435. doi:10.2147/DMSO.S45183
Isomaa B, Almgren P, Tuomi T, et al. Cardiovascular morbidity and mortality associated with the metabolic syndrome. Diabetes Care. 2001;24(4):683-689. doi:10.2337/diacare.24.4.683
Lakka HM, Laaksonen DE, Lakka TA, et al. The metabolic syndrome and total and cardiovascular disease mortality in middle-aged men. Jama. 2002;288(21):2709-2716. doi:10.1001/jama.288.21.2709
Executive summary of the third report of the National Cholesterol Education Program (NCEP) expert panel on detection, evaluation, and treatment of high blood cholesterol in adults (adult treatment panel III). Jama. 2001;285(19):2486-2497.
Zhang S, Wang Y, Cheng J, et al. Hyperuricemia and cardiovascular disease. Curr Pharm Des. 2019;25(6):700-709. doi:10.2174/1381612825666190408122557
Weinstock Brown W, Keane WF. Proteinuria and cardiovascular disease. Am J Kidney Dis. 2001;38(4 Suppl 1):S8-s13. doi:10.1053/ajkd.2001.27383